Exozymes (EXOZ) Other Non Operating Income (2023 - 2026)

Exozymes (EXOZ) posted quarterly Other Non Operating Income of -$196795.0 for Q4 2025, down 211.8% quarter-over-quarter from $176032.0 in Q3 2025.

Exozymes (EXOZ) Other Non Operating Income (2023 - 2026) Analysis & Trends

Exozymes (EXOZ) has reported Other Non Operating Income for 2 consecutive years, with -$196795.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Other Non Operating Income changed N/A year-over-year to -$196795.0; the TTM figure through Dec 2025 stood at $227258.0 (changed N/A YoY), while the FY2025 annual figure was $88746.0, down 62.26% from the prior year.
Other Non Operating Income retreated to -$196795.0 in Q4 2025 per EXOZ's latest filing, from $176032.0 in the prior quarter.
Across five years, Other Non Operating Income topped out at $176032.0 in Q3 2025 and bottomed at -$196795.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Exozymes	62.35 Mn	62.35 Mn	-

Download Data